Company intelligence / Profile preview

Kyungdong Pharmaceutical

Seoul, South Korea

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Kyungdong Pharmaceutical has developed and received approval for small molecule drugs such as clopidogrel camsylate (approved for thrombosis) and sibutramine sulfate (approved for obesity) in South Korea. The company maintains an active clinical pipeline in endocrinology, cardiovascular, metabolic, nervous system, and urinary indications with several diabetes and hypertension candidates in early clinical stages. Published literature describes the company's work in developing and optimizing formulations for drugs including dapagliflozin and metformin.

Therapeutic areas: NephrologyCardiovascularEndocrinologyInfectious DiseasesNeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

21 assets

KDF2001

Preclinical

20 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kyungdong Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kyungdong Pharmaceutical.

Explore the full profile